Summary
Existing lipid nanoparticle RNA vaccine formulations (LNPs) require high doses and are limited by high production costs, poor storage stability, and significant side effects. Imperial College London nanomaterial engineers (Stevens) and infectious disease RNA vaccinologists...
More information & hyperlinks
Web resources: | https://scholar.google.com/citations |